Microvascular responsiveness in obesity: implications for therapeutic intervention
Zsolt Bagi1, Attila Feher, James Cassuto
1Department of Pharmacology, University of Oxford, UK Department of Physiology, New York Medical College, Valhalla, New York, USA. zsolt.bagi@pharm.ox.ac.uk
British Journal of Pharmacology
|July 30, 2011
Summary
Obesity impairs blood vessel function, increasing cardiovascular risks. Targeting microcirculation in fat tissue may offer new ways to treat obesity and related vascular issues.
Area of Science:
- Cardiovascular Physiology
- Obesity Research
- Microvascular Function
Background:
- Obesity negatively impacts microcirculation and vascular responsiveness.
- This can heighten the risk of cardiovascular complications in obese individuals.
- Alterations in adipose tissue microcirculation may contribute to obesity development.
Purpose of the Study:
- To review studies on vasomotor dysfunction in resistance arteries of obese humans and animals.
- To contrast findings in coronary resistance arteries with other vascular beds.
- To explore therapeutic strategies for obesity-related microvascular complications.
Main Methods:
- Review of recent scientific literature on obesity and microvascular function.
- Comparative analysis of vasomotor dysfunction in different vascular beds.
- Examination of therapeutic interventions for microvascular complications.
Main Results:
- Obesity causes detrimental changes in microvascular responsiveness.
- Targeting microvessels, particularly in adipose tissue, shows potential for treating obesity and vascular complications.
- Statins, ACE inhibitors, and insulin sensitizers are among therapeutic examples.
Conclusions:
- Microvascular dysfunction is a key factor in obesity-related cardiovascular disease.
- Therapeutic strategies targeting microcirculation offer promising avenues for managing obesity and its vascular consequences.
- Further research is needed to address challenges and explore opportunities in this field.
More Related Videos
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...